Accordingly, the role of the combination of PD-1/CTLA-4 inhibitors is currently limited in patients with PD-L1-high and/or PD-L1-low advanced NSCLC, whereas it may be considered a potentially effective and tolerable option in PD-L1-negative subgroups (38). The gene discussed is CD274; the disease is non-small cell lung carcinoma.